Supriya Lifescience Ltd. Reports ₹145.07 Crore Revenue
35.6% EBITDA Margin in Q1 FY26 reported by the company
Supriya Lifescience Ltd., a cGMP-compliant global leader in Active Pharmaceutical Ingredients (APIs) across anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic segments, today announced its unaudited financial results for the first quarter of FY26. The company continues to strengthen its presence in over 86 countries worldwide.
Key Highlights – Q1 FY26
- Revenue: ₹145.07 crore, down 9.7% YoY (vs. ₹160.63 crore in Q1 FY25).
- EBITDA: ₹51.70 crore, with a margin of 35.6% (vs. ₹62.54 crore, margin 38.9% in Q1 FY25).
- PAT: ₹34.79 crore, margin 24.0% (vs. ₹44.64 crore, margin 27.8% in Q1 FY25).
- Business Mix: Anaesthetic segment led with 53% contribution to revenue (vs. 45% in Q1 FY25).
- Geography: European markets contributed 41% of revenue (vs. 34% in Q1 FY25).
- Capacity Utilisation: Improved to 76% in FY26 from 70% in FY25.
- Growth Initiatives: Acquisition of three land parcels near existing plants to support future expansion.
Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd., said: “Our Q1 results reflect a temporary impact from the delay in the production facility campaign due to essential repair and maintenance at our Lote facility. These upgrades were critical to improving the efficiency of our older blocks and enabling full utilisation of Module E for upcoming product launches. Despite the revenue dip, EBITDA margins remained strong at 36%, backed by improved backwards integration and increased contribution from regulated markets.
With the Ambernath site progressing towards commercial production in Q4, a strong pipeline of 3–4 product launches in FY26, and healthy demand across key therapeutic areas, we expect the second half to recover the delays from H1. We remain on track to deliver ~20% growth and reach ₹1,000 crore revenue by FY27.”
